Lonza Launches Sentinel APART™ Server-Based Platform Designed to Help Improve the Quality and Safety of Therapeutic Antibodies
- Platform enables prediction of aggregation risk in antibodies and guides antibody re-engineering to reduce aggregation
- Highly secure, customer dedicated, web-based application accessible from customers' facilities allows focus on fewer variants, ultimately reducing R&D time and cost
- High-throughput, easy-to-use screening and engineering tool complements in-house antibody discovery and development activities
Basel, Switzerland, 30 March 2016 – Lonza, a global leader in biological development and manufacturing, today announced the introduction of the Sentinel APART™ platform, a server-based antibody aggregation prediction and re-engineering tool. By using this high-throughput screening platform, customers can assess multiple candidates, which aids lead ranking and selection at the late discovery stage.
Therapeutic antibody aggregation issues can result in a higher risk of immunogenicity and delayed timelines, which can increase development costs and attrition rates. In addition, there is an increasing expectation from regulators for levels of aggregation to be identified, reported and addressed as part of the development process.
Lonza developed the Sentinel APART™ platform based on our extensive knowledge and expertise in antibody production and protein engineering. The tool was built and validated on experimental aggregation data for more than 500 antibodies. Using the primary sequence as input, it provides qualitative prediction (high or low) of aggregation risk for antibodies.
The protein re-engineering functionality of the platform identifies residues that contribute to aggregation and provides a guided approach for suitable amino acid substitutions. The tool calculates the change in aggregation risk for either one or two position substitutions, taking into consideration potential impact on post-translational modifications in the re-engineered antibody sequence. This guided approach reduces the need for extensive bioinformatics or protein modeling experience.
“The Sentinel APART™ platform supports our Customers' existing discovery and development activities by addressing a common issue found with therapeutic antibodies,” said Karen Fallen, Vice President, Business Unit Head, Clinical Development and Licensing for Lonza. “Our easy-to-use, high-throughput tool helps customers address the challenges in early development by assessing, designing and optimizing therapeutic antibodies for clinical success.”
To learn more about the Sentinel APART™ platform, please visit: www.lonza.com/sentinelapart.